Skip to main content

Advertisement

Table 7 Basic results. Cost-effectiveness analysis (Cost/QALY gained)a

From: Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

Years since initiation PSM vs PC PSM vs Hpc PSM vs Hvp PSM vs Dabi
1 12,289 € 4960 € 9120 € Dominant
2 3519 € Dominant 275 € Dominant
3 770 € Dominant Dominant Dominant
4 Dominant Dominant Dominant Dominant
5 Dominant Dominant Dominant Dominant
10 Dominant Dominant Dominant Dominant
Lifetime Dominant Dominant Dominant Dominant
  1. PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital with portable coagulometer; Hvp Hospital with venipuncture; Dabi Dabigatran
  2. aThe basic results are shown from the perspective of the health system. In the analysis from the social perspective, PSM was the dominant option in all cases except for the analysis at 1 year vs. PCpc, in which the iCER was 7352 € per QALY gained